Formulation and Evaluation of Hydroxypropyl Methylcellulose-based Controlled Release Matrix Tablets for Theophylline

Area of Science:

• Pharmaceutical Sciences
• Materials Science

Background:

• Controlled drug delivery systems aim to optimize therapeutic efficacy and patient compliance.
• Hydroxypropyl methylcellulose (HPMC) is a widely used polymer for developing sustained-release formulations due to its biocompatibility and gelling properties.
• Theophylline, a bronchodilator, requires controlled release to maintain therapeutic levels and minimize side effects.

Purpose of the Study:

• To formulate and characterize hydroxypropyl methylcellulose (HPMC)-based controlled-release matrix tablets of theophylline.
• To investigate the impact of varying drug:polymer ratios and tablet hardness on theophylline release kinetics.
• To evaluate the physico-chemical properties and stability of the optimized theophylline formulation.

Main Methods:

• Theophylline matrix tablets were prepared using the wet granulation technique with different drug:HPMC ratios (1:1, 1:2) and tablet hardness levels (5, 6, 7 kg/cm²).
• Granules were evaluated for flow properties (angle of repose, bulk density, tapped density, compressibility index, Hausner ratio).
• Tablet properties (hardness, weight uniformity, friability, drug content) and in vitro drug release (pH 7.4, paddle method) were assessed. FT-IR spectroscopy was used to check for drug-polymer interactions. Release kinetics were analyzed using the Korsmeyer-Peppas model.

Main Results:

• Granules exhibited good flow properties, and formulated tablets met acceptable physical standards.
• FT-IR analysis confirmed no significant interaction between theophylline and HPMC in the F-6 formulation.
• Formulation F-6 (1:2 drug:polymer ratio, 7 kg/cm² hardness) demonstrated prolonged theophylline release compared to other formulations.
• Theophylline release followed the Korsmeyer-Peppas model, indicating non-Fickian or anomalous diffusion.

Conclusions:

• HPMC-based matrix tablets can effectively control the release of theophylline.
• Increased drug:polymer ratio and tablet hardness significantly enhance the sustained release of theophylline.
• The optimized formulation (F-6) exhibited good stability over six months, suggesting its potential for clinical application.